We are a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease.
Copyright Nasdaq. Minimum 15 minutes delayed.
4:30 PM EDT
|Akebia's Fourth Quarter and Fiscal Year 2017 Financial Results|
8:00 AM EST
|RBC Capital Markets 2018 Global Healthcare Conference|
2:15 PM EST
|BIO CEO & Investor Conference|